Duration of the hypolipidemic effect after the course of intravenous laser therapy in patients with lipid metabolism disorders

Purpose: to fi nd the duration of hypolipidemic effect after the course of intravenous laser therapy in patients with coronary artery disease (CAD) and lipid metabolism disorders resistant to hypolipidemic pharmacotherapy.

Patients and methods. 40 patients with CAD and lipid metabolism disorders (LMD) resistant to hypolipidemic drugs were enrolled in the trial. Patients were divided into two comparable groups depending on the curative technique: 20 patients from Group 1 (main group) had intravenous laser blood irradiation (ILBI) and supportive medicamentous therapy (SMT). 20 patients from Group 2 (control group) had only SMT.

Results and discussion. Initially, patients in both groups had LMD signs despite of hypolipidemic drug therapy: elevated levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), atherogenic index (AI), and reduced high-density lipoprotein cholesterol (HDL-C) compared to normal values. Baseline values in both groups were statistically insignifi cant for TC, HDL-C, LDL-C and AI levels which indicated comparability between the groups. The study results demonstrated that patients in the main lasered group with ILBI course demonstrated much better hypolipidemic effect in 1 and 3 months after the treatment compared to baseline values: signifi cant reduction in TC by 19.1 % and 16.1 %, respectively; signifi cant reduction in LDL-C by 24.1 % and 21.8 %, respectively; signifi cant reduction in AI by 33.7 % and 29.1 %, respectively. Four months after the ILBI course, hypolipidemic effect became signifi cantly less evident, and lipid profi le indicators in the main group returned to baseline levels, except for total cholesterol. Therefore, in 4 months after ILBI course, patients require a repeated laser therapy course. The controls throughout the observation period had no signifi cant positive dynamics compared to baseline values.

Conclusion. In patients with CAD and LMD resistant to hypolipidemic drugs, ILBI therapy corrects LMD. It has been demonstrated by the signifi cant reduction in TC, LDL-C, and AI levels, as well as by increased HDL-C level, although lipid profi le parameters did not reach their normal or target values. The obtained positive effect persisted for 3 months after the course of laser therapy. After that, ILBI positive effect gradually went down, except the total cholesterol. That is why, in four months patients require a repeat course of laser therapy. To achieve a full hypolipidemic effect in this category of patient, it is necessary to develop and incorporate other non-drug curative techniques.

1. Achilov A.A., Baranov A.V., Achilova Sh.A., Lebedeva O.D., Kornev A.I., Airapetova T.L. Optimization of complex treatment of patients with severe arterial hypertension. Klinicheskaya gerontologia. 2021; 27 (1–2): 76–83 (In Russ.).

2. Streltsova N.N., Vasilyeva A.P. The mechanism and kinetics of the formation of the antianginal effect of laser therapy in patients with angina. Laser Medicine. 2023; 27 (2): 16–21. (In Russ.). DOI: 10.37895/2071-8004-2023-27-2-16-21

3. Oganov R.G. The importance of epidemiological studies and evidence-based medicine for clinical practice. Kardiovaskuliarnaya terapia i praktika. 2015; 14 (4): 4–7 (In Russ.).

4. Karpov Yu.A. How to implement a course for strengthening the control of low-density lipoprotein cholesterol in reducing cardiovascular risks? Atmosphera. Novosti kardiologii. 202; 1: 3–12 (In Russ.).

5. Karpov Yu.A. Effi ciency and safety in achieving new low target levels of low-density lipoprotein cholesterol: the role of combination therapy. Atmosphera. Novosti kardiologii. 2021; 2: 3–11 (In Russ.).

6. Karpov Yu.A., Barbarash O.L., Boschenko A.A., Kashtalap V.V., Kukharchuk V.V., etc. Eurasian clinical guidelines for diagnostics and treatment of stable coronary heart disease (2020–2021). Eurasijskiy kardiologicheskij zhurnal. 2021; 3 (36): 54–93 (In Russ.).

7. Giugliano R.P., Pedersen T.R., Park J.G., etc. Clinical effi cacy and safety of achieving very low LDL cholesterol concentrations with the PCSK9 inhibitor in evolocumab: a pre-determined secondary analysis of the FOURIER study. The Lancet. 2017; 390 (10106): 1962–1971. DOI: 10.1016/S0140-6736(17)32290-0

8. Bhatt D.L., Steg P.G., Miller M. et al. Reduction of cardiovascular risk with icozapent ethyl in hypertriglyceridemia. New England Journal of Medicine. 2019; 380 (1): 11–22. DOI: 0.1056/NEJMoa1812792

9. Collaboration of researchers in the fi eld of cholesterol treatment. Effi cacy and safety of statin therapy in the elderly: a meta-analysis of data from individual participants in 28 randomized controlled trials. The Lancet. 2019; 393 (10170): 407-415. DOI: 10.1016/S0140-6736(18)31942-1

10. Rohit D., Shankar J. Comparative study of atorvastatin and rosuvastatin in combination with fenofi brate in mixed hyperlipidemia. International Institute of Pharmacology and Clinical Science. 2016; 5 (1): 25–31.

11. Lee J., Egolum U., Parihar H., et al. Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. Cardiol Res. 2021; 12 (2): 98–108. DOI: 10.14740/cr1224

12. Ray K.K., Reeskamp L.F., Laufs U., et al. Combination lipidlowering therapy as fi rst-line strategy in very high-risk patients. Eur Heart J. 2022; 43 (8): 830–833. DOI: 10.1093/eurheartj/ehab718

13. Burnett H., Fahrbach K., Cichewicz A., et al. Comparative effi cacy of non-statin lipidlowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022; 38 (5): 777– 784. DOI: 10.1080/03007995.2022.2049164

14. Khan S.A., Naz A., Qamar Masood M., Shah R. MetaAnalysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020; 134: 69–73. DOI: 10.1016/j.amjcard.2020.08.018

15. Lloyd-Jones D.M., Morris P.B., Ballantyne C.M., et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am CollCardiol. 2022; 80 (14): 1366–1418. DOI: 10.1016/j.jacc.2022.07.006

16. Kukharchuk V.V., Yezhov M.V., Sergiyenko I.V., Arabidze G.G., Bubnova M.G. et al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Atheroscleros i dyslipidemia. 2020; 1 (38): 7–40 (In Russ.).

17. Moriarty P.M., Thompson P.D., Cannon C.P., et al. Effi cacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. Journal of clinical lipidology. 2015; 9 (6): 758-769. DOI: 10.1016/j.jacl.2015.08.006

18. Nissen S.E., Stroes E., Dent-Acosta R.E., et al. Effi cacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. Jama. 2016; 315 (15): 1580–1590. DOI: 10.1001/jama.2016.3608

19. Schreml J., Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Current medicinal chemistry. 2018; 25 (13): 1538–1548. DOI: 10.2174/0929867324666170616111647

20. Baranov A.V., Tsyganova G.I., Pimenova L.Ya., Kartusova L.N. The state of scientifi c research in the fi eld of photodynamic therapy in the Russian Federation in 2016–2017. Laser medicine. 2018; 22 (3): 44–49 (In Russ.).

21. Solovyova A.B., Spokoiny A.L., Rudenko T.G., Shekhter A.B., Glagolev N.N., Aksenova N.A., Baranov A.V. The infl uence of water-soluble polymers on the activity of photoditazine during photodynamic therapy of purulent soft tissue wounds in an experiment. Clinical practice. 2016; 2 (26): 45–49 (In Russ.).

22. Guseinov A.I., Baranov A.V., Radzhabov A.A., Derbenev V.A., Karandashov V.I., Aleksandrova N.P. Photodynamic therapy for periprosthetic joint infection. Laser medicine. 2021; 25 (1): 9–15 (In Russ.).

23. Baranov A.V., Shastina V.R., Gorin S.G., Guseinov A.I., Derbenev V.A., Kanaev A.S., Karandashov V.I., Mustafaev R.D., Radzhabov A.A. method of treating patients with periprosthetic infection after joint replacement. Patent for invention RU 2712806 C1, 01/31/2020. Application No. 2019115302 dated 05/20/2019.

24. Stranadko E.F., Baranov A.V., Duvansky V.A., Lobakov A.I., Morokhotov V.A., Ryabov M.V. Photodynamic therapy for cancer of the major duodenal papilla and extrahepatic bile ducts. Biomedical Photonics. 2020; 9 (2): 18–28 (In Russ.).

25. Alekseev Yu.V., Shiryaev V.S., Baranov A.V., Khosrovyan A.M., Babushkin V.Yu. Application of photolysis products of a chlorine series photosensitizer for the treatment of hospital-acquired pneumonia. Laser Medicine. 2023; 27 (1): 16–22 (In Russ.). DOI: 10.37895/2071-8004-2023-27-1-18-22

26. Vetrova Z.D., Achilov A.A., Fomichev V.I., Eliseenko V.I. The use of ozone therapy, alpha-fetoprotein and low–intensity laser radiation in the treatment of patients with coronary heart disease with concomitant hypertension. Laser medicine. 2012; 4: 33–37 (In Russ.).

27. Achilov A.A., Baranov A.V., Achilova Sh. A., Karandashov V.I., Gladko O.V. Application of low-level laser therapy and unloading therapeutic gymnastics in the complex treatment of severe hypertension. Lazernaya medicina. 2018; 22 (4): 6–10 (In Russ.).

28. Shpagin M.V., Yarikov A.V., Pavlov S.S., Sokolov A.A. The use of laser therapy in the complex treatment of patients with compression-ischemic neuropathy. Laser medicine. 2021; 25 (1): 36–44 (In Russ.). DOI: 10.37895/2071-8004-2021-25-136-44

29. Lutsenko Yu.G., Grintsov A.G., Matiytsiv A.B. The effectiveness of laser therapy in patients with diabetic foot. Laser medicine. 2022; 26 (3–4): 26–31 (In Russ.). DOI: 10.37895/2071-8004-2022-26-3-4-26-31

30. Lazareva E.N., Makashova V.V., Osipova E.G. Application of laser therapy for osteoarthritis (literature review). Laser medicine. 2023; 27 (1): 46–52 (In Russ.). DOI: 10.37895/20718004-2023-27-1-46-52

31. Gorchak Yu.Yu., Gens G.P., Prazdnikov E.N. et al. Possibilities of low-intensity laser radiation in the rehabilitation treatment of cancer patients. Laser Medicine. 2021; 25 (3): 47–58. (In Russ.). DOI: 10.37895/2071-8004-2021-25-3-47-58

32. Ryazantsev V.E., Vlasov A.P., Mashnin I.V. Application of low-intensity laser radiation in the complex treatment of acute kidney injury. Laser Medicine. 2020; 24 (4): 18–23 (In Russ.). DOI: 10.37895/2071-8004-2020-24-4-19-23

33. Achilov A.A., Almazov I.I., Kulikova T.V., Borisova G.A., Sidorenko B.A. The state of the microvasculature, hemoperfusion and tissue oxygen regime in patients with coronary heart disease with angina pectoris. Ter. Archive. 1984; 6: 39–43 (In Russ.).